Observational studyMedicine2025
Association of neutrophil-to-lymphocyte ratio (NLR) and neutrophil-to-monocyte-to-lymphocyte ratio (NMLR) with mortality in adults with osteoarthritis: Evidence from NHANES 2001 to 2018.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) and the neutrophil-to-monocyte-to-lymphocyte ratio (NMLR) in osteoarthritis (OA) remains unclear. This study aimed to explore the association between biomarkers and clinical outcomes in OA patients. Data from the National Health and Nutrition Examination Survey (NHANES) spanning 2001 to 2018 were used in this study. Kaplan-Meier survival analysis, multivariable Cox hazard regression analysis, and restricted cubic spline (RCS) were used to assess mortality associations and nonlinear relationships. Subgroup and sensitivity analyses were performed to ensure the robustness and reliability. A total of 578 all-cause deaths and 190 cardiovascular deaths were recorded. The Kaplan-Meier analyses indicated reduced survival among individuals with the highest NLR and NMLR levels. Multivariable Cox regression analysis showed that elevated NLR was associated with higher all-cause mortality (HR = 1.17, 95% CI: 1.08-1.25; P < .001) and approached statistical significance for increased cardiovascular mortality (HR = 1.14, 95% CI: 0.99-1.29; P = .053). Elevated NMLR was significantly associated with higher all-cause mortality (HR = 1.16, 95% CI: 1.08-1.24; P < .001) and cardiovascular mortality (HR = 1.13, 95% CI: 1.01-1.28; P = .041). The RCS model indicated that NLR was nonlinearly associated with all-cause and cardiovascular mortality, with an inflection point at 2.04 for both outcomes. The NMLR was nonlinearly associated with all-cause and cardiovascular mortality, with an inflection point at 2.32 for both outcomes. Subgroup analyses showed the association between NLR/NMLR and all-cause mortality was more significant in individuals aged ≥ 60 years (P for interaction < .05). NLR and NMLR are associated with an elevated risk of all-cause and cardiovascular mortality in OA individuals. Both biomarkers may serve as useful indicators for assessing inflammatory burden and offer promising clinical prospects for risk stratification and disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.